Evidence map›Paper›PMID 42756094›Full record

ReviewFrontiers in immunology2026

Traditional Chinese medicine remodels the immune microenvironment of colorectal cancer: mechanisms and therapeutic perspectives.

Zeanbang Shi, Jie Mei, Qinchang Zhang, Liu Li, Haibo Cheng

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Zeanbang ShiThe First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, China.
Jie MeiThe First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, China.
Qinchang ZhangThe First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, China.
Liu LiThe First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, China.
Haibo ChengThe First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer (CRC) is a common malignancy of the digestive tract, and its initiation and progression are closely associated with dysregulation of the tumor immune microenvironment. The CRC immune microenvironment consists of effector immune cells, immunosuppressive cells, inflammatory mediators, immune checkpoint pathways, stromal cells, the extracellular matrix, the gut microbiota, and microbial metabolites. Its pathological features include impaired immune recognition and effector immunity, enhanced immunosuppression, extracellular matrix remodeling-mediated immune exclusion, dysregulated inflammatory and immune checkpoint signaling, and disturbances in gut microbiota and metabolism. Traditional Chinese medicine (TCM), characterized by multicomponent, multitarget, and multilevel regulation, has shown potential value in research on the CRC immune microenvironment. Current preclinical studies suggest that TCM-derived isolated compounds and bioactive constituents, single herbs, Chinese herbal formulas, and Chinese patent medicines may improve immune recognition and effector immune function by restoring antigen presentation, promoting dendritic cell maturation and enhancing effector T-cell responses and natural killer cell activity. These interventions may also inhibit immunosuppressive cells, modulate immune checkpoint and inflammation-related signaling, and enhance antitumor immunity by inducing immunogenic forms of tumor cell death. In addition, TCM may alleviate immunosuppression and immune exclusion by modulating stromal remodeling mediated by cancer-associated fibroblasts and regulating the gut microbiota, microbial metabolites, and tumor immunometabolism. In some preclinical models, these effects enhanced the antitumor efficacy of immune checkpoint blockade and provided experimental support for further mechanistic validation and clinical studies of TCM combined with immunotherapy. However, current evidence remains predominantly preclinical, and further clinical validation and assessment of bioavailability, safety, and drug interactions are needed. This review summarizes the composition and pathological features of the CRC immune microenvironment and discusses recent advances in TCM-mediated immune modulation. It also examines current mechanistic evidence and its limitations to inform further mechanistic validation, clinical study design, and translational research.

Indexed as

Colorectal NeoplasmsDrugs, Chinese HerbalMedicine, Chinese TraditionalTumor MicroenvironmentAnimalsGastrointestinal MicrobiomeHumansDrugs, Chinese Herbalcolorectal cancerextracellular matrix remodelinggut microbiotaimmunotherapytraditional Chinese medicinetumor immune microenvironment

Identifiers

PMID42756094
PMCPMC13582557

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.